Leishmania resistance to miltefosine associated with genetic marker

Emerging Infectious Diseases

Volumn 18, Issue 4, 2012, Pages 704-706

  Cojean, Sandrine ^a   Houzé, Sandrine ^b   Haouchine, Djamel ^b   Huteau, Françoise ^a   Lariven, Sylvie ^b   Hubert, Véronique ^b   Michard, Florence ^b   Bories, Christian ^a   Pratlong, Francine ^c   le Bras, Jacques ^b   Loiseau, Philippe Marie ^a   Matheron, Sophie ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE;

ALLELE; AMASTIGOTE; CASE REPORT; DRUG SENSITIVITY; DRUG WITHDRAWAL; FOLLOW UP; GENETIC MARKER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LETTER; PROMASTIGOTE; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PHOSPHORYLCHOLINE; RECURRENCE;

EID: 84858649702     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1804.110841     Document Type: Letter

References (8)

1. Vieira NC, Herrenknecht C, Vacus J, Fournet A, Bories C, Figadère B, et al. Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomed Pharmacother. 2008;62:684-9. http://dx.doi.org/10.1016/j.biopha.2008.09.002
2. Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, Maes L. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother. 2009;53:3855-9. http://dx.doi.org/10.1128/AAC.00548-09
3. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 1998;42:352-7.
4. Seifert K, Matu S, Perez-Victoria J, Castanys S, Gamarro F, Croft SL. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents. 2003;22:380-7. http://dx.doi.org/10.1016/S0924-8579(03)00125-0
5. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem. 2003;278:49965-71. http://dx.doi.org/10.1074/jbc.M308352200
6. Seifert K, Pérez-Victoria FJ, Stettler M, Sánchez-Cañete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30:229-35. http://dx.doi.org/10.1016/j.ijantimicag.2007.05.007
7. Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat. 2006;9:26-39. http://dx.doi.org/10.1016/j.drup.2006.04.001
8. Sánchez-Cañete MP, Carvalho L, Pérez-Victoria FJ, Gamarro F, Castanys S. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother. 2009;53:1305-13. http://dx.doi.org/10.1128/AAC.01694-08